Terazosin Capsule
Product Images NDC 50268-767

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 50268-767). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avpak, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1mg (764 15 1mg)

Label for Terazosin Capsules, USP 1 mg by AvPAK, containing 50 capsules (5 x 10 unit dose) for oral use. The label includes storage instructions, dosage acknowledgment, and a reminder to dispense with the patient information sheet. Manufactured for AvKARE in Pulaski, TN.*

FDA Label Image

2mg (765 15 2mg)

Label for Terazosin Capsules, USP 2 mg, prescription oral capsules. The unit dose package contains 50 capsules (5 x 10). The label includes dispensing instructions, storage conditions (20°-25°C), and manufacturer information for AvPAK, Pulaski, TN. The product is marked Rx only and includes the NDC 50268-765-15 with barcode.*

FDA Label Image

5mg (766 15 5mg)

Terazosin Capsules, USP 5 mg oral capsules label showing a 50-capsule (5 x 10) unit dose package. The label includes the NDC 50268-766-15, states Rx only, and features the AvPAK logo. Instructions for pharmacists and storage conditions are also present, along with manufacturer information for AvKARE in Pulaski, TN.*

FDA Label Image

10mg (767 15 10mg)

Terazosin Capsules USP 10 mg oral capsules packaging label. The label states a quantity of 50 capsules in unit dose format (5 x 10) and is marked Rx Only. It includes the NDC 50268-767-15 and a barcode. The label specifies the product contains terazosin hydrochloride equivalent to 10 mg terazosin per capsule and includes storage instructions, dispensing directions, and manufacturer details for AvPAK, Pulaski, TN.*

FDA Label Image

Terazosin Hydrochloride Chemical Structure (Terazosin Hydrochloride Capsules 1)

Chemical structure of Terazosin Hydrochloride, showing the molecular arrangement of its key functional groups including aromatic rings, amine groups, and an amide linkage with the hydrochloride component.*

FDA Label Image

Figure 1 (Terazosin Hydrochloride Capsules 2)

The image shows two line graphs comparing placebo and terazosin groups over 3 months. The left graph depicts the mean change in total symptom score from baseline, with terazosin showing a greater decrease. The right graph shows the mean increase in peak flow rate (mL/sec) from baseline, with terazosin showing a greater increase compared to placebo. Sample sizes (N) are indicated for both groups.*

FDA Label Image

Figure 2 (Terazosin Hydrochloride Capsules 3)

Line graph depicting mean change from baseline over a 30-month period, with data points at various months from 0 to 30. The y-axis shows mean change values ranging approximately from 0 to -7, and several points are marked with asterisks indicating statistical significance.*

FDA Label Image

Figure 3 (Terazosin Hydrochloride Capsules 4)

A line graph depicting mean change from baseline in a measured variable over a 30-month period. The x-axis represents time in months from 0 to 30, and the y-axis indicates the mean change values from 0 to 4.5. Data points show an increasing trend that plateaus after month 12, with several points marked by asterisks indicating statistical significance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.